Drug class profile · refreshed daily from federal data

SGLT2 Inhibitor (Antidiabetic)

2 molecules in this class, $364.8M combined CY2024 Part D spend across 345K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the SGLT2 Inhibitor (Antidiabetic) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $364.8Mcombined across class
Total Rx claims: 345K92K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Canagliflozin

Brand: INVOKANA · 345K Part D claims (CY24) · 92K beneficiaries · First FDA approval: 2013-03-29

Brand-only (no generics) 0 plans require PA

Low NADAC$19.10

→

Avg plan cost$19.11

Part D spend $364.8M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Dapagliflozin

Brand: FARXIGA · — Part D claims (CY24) · First FDA approval: 2008-01-14

Brand-only (no generics) 0 plans require PA

Low NADAC$0.185

→

Avg plan cost$8.68

Part D spend — 47× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.